Dodge & Cox Has $1.67 Billion Stock Holdings in Elanco Animal Health Incorporated $ELAN

Dodge & Cox trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 0.2% in the third quarter, Holdings Channel reports. The firm owned 82,759,837 shares of the company’s stock after selling 135,395 shares during the quarter. Dodge & Cox owned about 0.17% of Elanco Animal Health worth $1,666,783,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. UBS Group AG boosted its holdings in shares of Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Bowen Hanes & Co. Inc. acquired a new position in Elanco Animal Health during the third quarter worth $47,626,000. Dimensional Fund Advisors LP increased its holdings in Elanco Animal Health by 8.6% during the third quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock worth $497,610,000 after buying an additional 1,962,276 shares during the last quarter. Finally, Jupiter Asset Management Ltd. raised its position in Elanco Animal Health by 98.8% during the third quarter. Jupiter Asset Management Ltd. now owns 3,716,849 shares of the company’s stock worth $74,857,000 after acquiring an additional 1,846,907 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on ELAN shares. Leerink Partners lifted their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. Morgan Stanley raised their target price on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Wednesday, November 19th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Elanco Animal Health Trading Up 1.2%

ELAN stock opened at $22.95 on Friday. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $27.72. The stock has a market cap of $11.41 billion, a price-to-earnings ratio of -47.80, a price-to-earnings-growth ratio of 2.89 and a beta of 1.83. The company has a fifty day moving average price of $24.52 and a two-hundred day moving average price of $22.19. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company’s revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.